Humira®
Adalimumab
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$84,000/year (US list price 2024)
With Insurance
$0–200/month (with copay card)
How It Works
Adalimumab is a laboratory-engineered antibody that hunts and neutralizes a single inflammatory protein — TNF-alpha. By blocking TNF-alpha before it can bind to cell receptors, it shuts down a critical amplification loop of the immune system's inflammatory cascade.
Why the side effects happen
TNF-alpha is a critical part of the immune system's defense against infections — it helps recruit immune cells to fight bacteria, fungi, and viruses. Blocking it system-wide reduces the body's ability to contain these threats. TB reactivation occurs because TNF is essential for maintaining granulomas that contain latent TB bacteria. Lymphoma risk is increased because TNF also plays a role in tumor surveillance.
When Will I Feel It?
Inflammatory markers start falling within 2–4 weeks. Clinical response in RA typically visible at 12 weeks. Maximum benefit takes 6 months. Non-response by 24 weeks indicates the drug won't work for that patient.
CRP and other inflammatory markers begin falling. Some patients notice reduced morning stiffness.
ACR20 response (20% improvement in RA symptoms) achieved in responders. This is the first formal clinical milestone in trials.
Significant joint protection and functional improvement in RA responders. IBD patients typically show mucosal healing signals by this point.
Maximum disease control for responders. Disease activity score (DAS28) at target in most who will respond.
Adherence Note
If you have not responded by week 24, you are considered a primary non-responder — adalimumab is unlikely to work. Discuss switching to a different biologic mechanism (IL-6 inhibitor like tocilizumab, or a JAK inhibitor like upadacitinib). Stopping Humira always carries disease flare risk — never stop without specialist guidance.
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Injection site reactions (pain, redness, swelling)
20%Warm the pen to room temperature for 20–30 minutes before injecting; rotate injection sites; use ice after.
Upper respiratory infections (colds, sinusitis)
17%Expected due to TNF suppression. Wash hands frequently; avoid close contact with sick individuals. Report any infection to your doctor promptly.
Headache
12%Usually mild; OTC pain relievers (not NSAIDs if on other anti-inflammatory therapy) can help.
Rash
12%Various types: injection site, psoriasiform, or eczematoid. Report new rashes — some may be drug-related psoriasis (paradoxical reaction).
Nausea
9%Usually mild; take injection at bedtime if nausea is an issue.
Fatigue
7%Often improves as disease responds to treatment. May reflect underlying disease activity rather than drug effect.
Serious Adverse Effects
- • Serious infections — bacterial, fungal (histoplasmosis, coccidioidomycosis), viral, TB reactivation. Black box warning. Screen and treat latent TB before starting.
- • Malignancy — black box warning: increased risk of lymphoma and other cancers, particularly in patients with heavy prior immunosuppressant use
- • Hepatosplenic T-cell lymphoma — rare, often fatal; mainly in young males with IBD on Humira + azathioprine combination
- • Demyelinating disease — new-onset or worsening MS and other demyelinating conditions reported
- • Heart failure — worsening of pre-existing CHF; do not use in severe heart failure
- • Lupus-like syndrome — drug-induced lupus resolves on stopping
- • Reactivation of hepatitis B — screen before starting; prophylaxis required for chronic HBV carriers
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.
Contact soon if you notice
- Serious infections — bacterial, fungal (histoplasmosis, coccidioidomycosis), viral, TB reactivation. Black box warning. Screen and treat latent TB before starting.
- Malignancy — black box warning: increased risk of lymphoma and other cancers, particularly in patients with heavy prior immunosuppressant use
- Hepatosplenic T-cell lymphoma — rare, often fatal; mainly in young males with IBD on Humira + azathioprine combination
- Demyelinating disease — new-onset or worsening MS and other demyelinating conditions reported
- Rapid return of joint pain and swelling
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups — discuss with your provider before use.
Crosses placenta in 3rd trimester — newborn may have suppressed immunity for up to 5 months. Avoid live vaccines in infant for 5 months after birth. Discuss with rheumatologist — stopping during pregnancy must be weighed against disease flare risk.
Very low levels in breast milk; large molecule is poorly absorbed by infant. Most guidelines consider compatible with breastfeeding. Discuss with doctor.
Autoimmune conditions treated by Humira — including rheumatoid arthritis, Crohn's, and psoriasis — can change in activity around menopause. Some conditions temporarily worsen during perimenopause, which can lead to dose escalation that may not be needed long-term. Discuss with your specialist whether hormonal changes are contributing to any flare in symptoms.
FDA approved for JIA (2–17), Crohn's (6+), plaque psoriasis (4+), UC (5+). Lymphoma risk is a concern — especially with concurrent thiopurines.
Elderly patients have higher baseline infection risk. Monitor closely for infections. TB screening is especially important. Carefully assess benefit-risk in those with multiple comorbidities.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences — anonymous & anecdotal
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Metabolic & Lifestyle Alternatives
🥗 Autoimmune Inflammation: Addressing Root Causes
Emerging evidence shows that dietary and lifestyle interventions can substantially reduce autoimmune inflammation — and in some cases achieve remission without biologics
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Mediterranean / anti-inflammatory diet
ModerateOlive oil, fatty fish, vegetables, legumes; eliminate processed foods
Multiple RCTs in RA show Mediterranean diet reduces DAS28 (disease activity) score, CRP, and pain. Anti-inflammatory effect is meaningful.
Omega-3 (EPA+DHA 3–4g/day)
ModerateHigh-dose fish oil or algae oil
Meta-analyses: omega-3 reduces joint tenderness, morning stiffness, and NSAID requirements in RA. Reduces TNF-alpha and IL-1 production — the same pathway Humira targets.
Specific Carbohydrate Diet (SCD) for IBD
ModerateElimination of disaccharides, grains, processed sugar
Clinical remission rates of 50–60% in pediatric Crohn's in RCT; comparable to standard dietary therapy for inducing remission in mild-moderate IBD
Methotrexate (DMARD — prior to biologic)
StrongTraditional DMARD; much cheaper, proven efficacy
Evidence-based first-line DMARD for RA. Many patients achieve adequate disease control on methotrexate alone, without needing a biologic. Cost: ~$10–20/month.
Supervised aerobic + resistance exercise
Moderate150 min/week mixed exercise program
Multiple RCTs: exercise reduces RA disease activity scores, pain, and fatigue. Does not worsen joint damage. Should be part of any RA management plan.
Key Studies
How It Compares
Humira is the most-prescribed biologic historically but biosimilars are now available at 20–40% lower cost with identical clinical outcomes. Non-TNF biologics offer alternatives for non-responders.
Strengths
- Most extensive real-world safety data of any biologic
- Multiple approved indications
- Subcutaneous injection (can self-administer at home)
- Biosimilars now available in US since 2023
Weaknesses
- $84,000/year US list price (EU equivalent: $9,000)
- Requires latent TB and HBV screening before starting
- Serious infection risk (bacterial, fungal, TB reactivation)
- Lymphoma risk (especially with concomitant thiopurines)
- Must continue indefinitely — stopping causes disease return
Clinically Preferred Alternatives
Global Prescribing & Pricing
United States
$5,500–7,000 (list)/mo
Most expensive market globally; patent thicket blocked biosimilars until 2023
AbbVie's 100+ patent strategy was legal under US law. Medicare Part D could not negotiate drug prices until 2022 Inflation Reduction Act. US patients and insurers paid the world's highest prices for 20 years.
Covered with prior authorization; copay cards available
United Kingdom
~$750–1,200/mo
NHS biosimilar adalimumab mandatory — 80–90% cost reduction
NHS implemented mandatory biosimilar switching for adalimumab in 2019. All stable patients were transitioned. NHS saved hundreds of millions. Clinical outcomes are equivalent.
NHS — biosimilar mandatory
Germany
~$800–1,400/mo
AMNOG price negotiation caps reimbursement; biosimilars widely used
Germany's AMNOG law requires evidence-based price negotiation. Biosimilars are incentivized through prescribing quotas. Reference pricing keeps biologic costs far below US.
GKV covered
India
~$200–400/mo
Biosimilar adalimumab widely available; domestic manufacturing
Multiple Indian biosimilar manufacturers produce adalimumab. Government price controls cap biologics. Same molecule, fraction of the cost.
Government schemes partially covered
Canada
~$1,200–1,800/mo
Biosimilars gaining market share; provincial reimbursement prefers biosimilars
Several Canadian provinces now require biosimilar use for new patients and stable patients being renewed. Cost savings redirected to fund other medications.
Provincial plans with biosimilar preference
The US-EU price gap for Humira — $84,000 vs $9,000 per year — is not explained by manufacturing costs or clinical evidence. It is the direct result of AbbVie's 100+ patent strategy and the US government's failure to allow Medicare to negotiate prices until 2022. UK patients on NHS biosimilars receive the same clinical outcomes at 90% less cost.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Funding Sources
Humira is the most profitable drug in human history — generating over $200 billion in cumulative revenue, peaking at $21.2 billion in 2022. AbbVie filed more than 100 patents on Humira, creating a "patent thicket" that successfully blocked biosimilar competition in the United States until January 2023 — 5 years after biosimilars became available in Europe. During those 5 years, the US price for Humira rose from approximately $44,000/year to $84,000/year, while European patients paid ~$9,000/year for the same molecule. The Institute for Clinical and Economic Review (ICER) estimates the fair price of adalimumab based on clinical value is $10,000–30,000/year.
Declared Conflicts of Interest
AbbVie funded all major pivotal trials. Independent researchers have noted that industry-funded biologic trials consistently show larger effect sizes than independently replicated studies. AbbVie's patient assistance programs — while helping some — also serve to obscure the true market price and create insurer dependency.
Key Efficacy Results
ACR20 response (20% symptom improvement) in ~65% of RA patients at 24 weeks. Effective for Crohn's, UC, psoriasis, psoriatic arthritis, AS. Requires ongoing treatment — disease returns within weeks of stopping. Does not modify the underlying immune dysregulation.
Referenced Studies
Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Adalimumab. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Adalimumab in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| ARMADA Trial — RA (NEJM 2003) | PMID:12621032 | |
| ICER Fair Pricing Analysis — Biologics | ICER-Report |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.
Our MethodologyMedical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Stopping This Medication Safely
Humira does not cause physical dependence, but stopping it causes the underlying autoimmune disease to return — often rapidly and severely. In RA, stopping Humira typically causes disease flare within 8–16 weeks. In Crohn's, remission is often lost within months. Any attempt to stop should be done in consultation with your rheumatologist or gastroenterologist, ideally with a plan for monitoring and rescue therapy.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Research documents that stopping without specialist guidance risks disease flare — in RA, this can cause irreversible joint damage
- ·Published guidelines describe holding 1–2 weeks before elective surgery and restarting once fully recovered
- ·Tapering strategies, such as extended dosing intervals, are documented in emerging research for well-controlled disease — rheumatologist guidance is recommended
- ·Research supports optimizing lifestyle interventions (diet, omega-3, exercise) before any dose reduction
- ·Research consistently documents that biosimilar switching produces equivalent clinical outcomes at 60–80% cost savings
Warning Symptoms — Contact Your Doctor If You Experience:
- Rapid return of joint pain and swelling
- Fever above 38.5°C / 101°F — could be infection or disease flare
- Significant fatigue, new rash, or joint deformity
- Abdominal pain and bleeding (IBD patients)
- Any new neurological symptoms — demyelination risk
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
Questions to Ask
- 1.Have conventional DMARDs (methotrexate, sulfasalazine, hydroxychloroquine) been fully optimized before escalating to a biologic?
- 2.What biosimilar alternatives to Humira are available, and why specifically the brand-name version at $7,000/month?
- 3.Have I been screened for latent TB and hepatitis B — and what is the vaccination plan before I start?
- 4.What does disease monitoring look like — what measures tell us this is working, and what is the plan if it stops working?
- 5.I am planning to become pregnant — what is the safest approach to Humira during pregnancy and breastfeeding?
Lab Tests to Request
- QuantiFERON-TB Gold or TB skin test (mandatory before starting)
- Hepatitis B surface antigen and core antibody
- Hepatitis C antibody
- CBC and CMP (baseline)
- ANA (antinuclear antibody — baseline for lupus monitoring)
- Lipid panel (biologics can affect lipids)
- Varicella and pneumococcal vaccine status
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions About Humira®
- What is Humira® used for?
- Humira® (Adalimumab) is a TNF-alpha Inhibitor (Biologic) manufactured by AbbVie. FDA-approved indications include: Rheumatoid arthritis; Psoriatic arthritis; Ankylosing spondylitis; Crohn's disease; Ulcerative colitis; Plaque psoriasis; Juvenile idiopathic arthritis; Hidradenitis suppurativa; Uveitis.
- What are the common side effects of Humira®?
- Common side effects of Humira® include: Injection site reactions (pain, redness, swelling) (20%); Upper respiratory infections (colds, sinusitis) (17%); Headache (12%); Rash (12%); Nausea (9%).
- How much does Humira® cost?
- Humira® list price is approximately $84,000/year (US list price 2024). With insurance it typically costs $0–200/month (with copay card); without insurance approximately $6,000–7,000/month (US list price).
- Who funded the clinical trials for Humira®?
- Humira is the most profitable drug in human history — generating over $200 billion in cumulative revenue, peaking at $21.2 billion in 2022. AbbVie filed more than 100 patents on Humira, creating a "patent thicket" that successfully blocked biosimilar competition in the United States until January 2023 — 5 years after biosimilars became available in Europe. During those 5 years, the US price for Humira rose from approximately $44,000/year to $84,000/year, while European patients paid ~$9,000/year for the same molecule. The Institute for Clinical and Economic Review (ICER) estimates the fair price of adalimumab based on clinical value is $10,000–30,000/year.
- How strong is the clinical evidence for Humira®?
- Key studies: ARMADA trial (RA, 2003), CHARM trial (Crohn's), ULTRA trials (UC), multiple AbbVie-funded pivotal trials. ACR20 response (20% symptom improvement) in ~65% of RA patients at 24 weeks. Effective for Crohn's, UC, psoriasis, psoriatic arthritis, AS. Requires ongoing treatment — disease returns within weeks of stopping. Does not modify the underlying immune dysregulation. Potential conflicts of interest: AbbVie funded all major pivotal trials. Independent researchers have noted that industry-funded biologic trials consistently show larger effect sizes than independently replicated studies. AbbVie's pa.
- Are there non-drug alternatives to Humira®?
- Emerging evidence shows that dietary and lifestyle interventions can substantially reduce autoimmune inflammation — and in some cases achieve remission without biologics See the Alternatives tab for full details.
Get notified when we update Humira®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.